The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer.
暂无分享,去创建一个
Yusuke Nakamura | Eiju Tsuchiya | Atsushi Takano | Tatsuya Kato | Tomoo Ito | Yusuke Nakamura | S. Sone | W. Yasui | Y. Daigo | K. Inai | Chiyuki Furukawa | Yataro Daigo | Nobuhisa Ishikawa | Saburo Sone | A. Takano | Wataru Yasui | E. Tsuchiya | Kouki Inai | N. Ishikawa | Tatsuya Kato | S. Hayama | Tomoo Ito | Hitoshi Nishimura | Chie Suzuki | Koji Takahashi | Satoshi Hayama | H. Nishimura | Chie Suzuki | Koji Takahashi | Chiyuki Furukawa
[1] N. Bunnett,et al. Regulatory mechanisms that modulate signalling by G-protein-coupled receptors. , 1997, The Biochemical journal.
[2] Taylor Murray,et al. Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.
[3] R. Osamura,et al. Ghrelin and growth hormone (GH) secretagogue receptor (GHSR) mRNA expression in human pituitary adenomas , 2001, Clinical endocrinology.
[4] Patrick R. Griffin,et al. A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release , 1996, Science.
[5] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[6] O. Nishimura,et al. Identification of Neuromedin U as the Cognate Ligand of the Orphan G Protein-coupled Receptor FM-3* , 2000, The Journal of Biological Chemistry.
[7] M. Nakazato,et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach , 1999, Nature.
[8] A. Beaudet,et al. Ligand-induced internalization of neurotensin in transfected COS-7 cells: differential intracellular trafficking of ligand and receptor. , 2000, Journal of cell science.
[9] U. Kumar,et al. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. , 2000, Science.
[10] C. Caldas,et al. A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples , 2003, Molecular pathology : MP.
[11] A. Datta,et al. Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. , 2004, Genes & development.
[12] C. Delporte,et al. Ghrelin is produced by the human erythroleukemic HEL cell line and involved in an autocrine pathway leading to cell proliferation. , 2005, Endocrinology.
[13] G. Sozzi. Molecular biology of lung cancer. , 2001, European journal of cancer.
[14] David Harrington,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.
[15] L. Thim,et al. Rabbit neuromedin U-25: lack of conservation of a posttranslational processing site , 1991, Regulatory Peptides.
[16] D. Schöevaërt,et al. Pathways of internalization of the hCG/LH receptor: immunoelectron microscopic studies in Leydig cells and transfected L-cells , 1992, The Journal of cell biology.
[17] R. Zeillinger,et al. Identification of L1CAM, Jagged2 and Neuromedin U as ovarian cancer-associated antigens. , 2005, Oncology reports.
[18] C. H. Cheng,et al. Identification and functional characterization of two alternatively spliced growth hormone secretagogue receptor transcripts from the pituitary of black seabream Acanthopagrus schlegeli , 2004, Molecular and Cellular Endocrinology.
[19] David E. Misek,et al. Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. , 2003, The American journal of pathology.
[20] L. Heasley,et al. Autocrine and paracrine signaling through neuropeptide receptors in human cancer , 2001, Oncogene.
[21] M. Ghatei,et al. Characterization of neuromedin U like immunoreactivity in rat, porcine, guinea-pig and human tissue extracts using a specific radioimmunoassay. , 1986, Biochemical and biophysical research communications.
[22] M. Nakazato,et al. Purification and identification of neuromedin U as an endogenous ligand for an orphan receptor GPR66 (FM3). , 2000, Biochemical and biophysical research communications.
[23] Yusuke Nakamura,et al. Plakophilin 3 oncogene as prognostic marker and therapeutic target for lung cancer. , 2005, Cancer research.
[24] Yusuke Nakamura,et al. ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway. , 2005, Cancer research.
[25] G. Yancopoulos,et al. Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[26] M. Teh,et al. FOXM1 is a downstream target of Gli1 in basal cell carcinomas. , 2002, Cancer research.
[27] S. Legon,et al. Distribution and developmental pattern of neuromedin U expression in the rat gastrointestinal tract. , 1994, Journal of molecular endocrinology.
[28] Yusuke Nakamura,et al. ADAM8 as a Novel Serological and Histochemical Marker for Lung Cancer , 2004, Clinical Cancer Research.
[29] Y. Yiangou,et al. The distribution, purification, and pharmacological action of an amphibian neuromedin U. , 1989, The Journal of biological chemistry.
[30] Christopher P. Austin,et al. Identification of receptors for neuromedin U and its role in feeding , 2000, Nature.
[31] A. Gewirtz,et al. Neuromedin U: a Myb-regulated autocrine growth factor for human myeloid leukemias. , 2004, Blood.
[32] J. Polak,et al. Localization of 7B2, neuromedin B, and neuromedin U in specific cell types of rat, mouse, and human pituitary, in rat hypothalamus, and in 30 human pituitary and extrapituitary tumors. , 1988, Endocrinology.
[33] Carlos Caldas,et al. Molecular Classification of Breast Carcinomas Using Tissue Microarrays , 2003, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[34] C. Lawrence,et al. Printed in U.S.A. Copyright © 2002 by The Endocrine Society doi: 10.1210/en.2002-220121 Evaluation of Neuromedin U Actions in Energy Homeostasis and Pituitary Function , 2022 .
[35] F. Monsma,et al. Cloning and characterization of murine neuromedin U receptors , 2002, Peptides.
[36] Michel Bouvier,et al. Oligomerization of G-protein-coupled transmitter receptors , 2001, Nature Reviews Neuroscience.
[37] Yusuke Nakamura,et al. Advances in Brief Identification of COX 17 as a Therapeutic Target for Non-Small Cell Lung Cancer 1 , 2003 .
[38] N. Minamino,et al. Neuromedin U-8 and U-25: novel uterus stimulating and hypertensive peptides identified in porcine spinal cord. , 1985, Biochemical and biophysical research communications.
[39] Teuvo Kohonen,et al. The self-organizing map , 1990 .
[40] S. Bloom,et al. Cloning and characterization of the cDNA encoding the human neuromedin U (NmU) precursor: NmU expression in the human gastrointestinal tract. , 1995, Journal of molecular endocrinology.
[41] J. Edwardson,et al. Endocytosis and recycling of G protein-coupled receptors. , 1997, Trends in pharmacological sciences.
[42] A. Beaudet,et al. Somatodendritic internalization and perinuclear targeting of neurotensin in the mammalian brain , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[43] 加藤 達哉. A novel human tRNA-dihydrouridine synthase involved in pulmonary carcinogenesis , 2005 .
[44] M. Ikawa,et al. Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway , 2004, Nature Medicine.
[45] Yusuke Nakamura,et al. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. , 2005, Cancer research.
[46] Yusuke Nakamura,et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs , 2003, Oncogene.
[47] L. Devi,et al. Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking. , 2001, Trends in pharmacological sciences.
[48] Yusuke Nakamura,et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). , 2004, Human molecular genetics.
[49] H. Lother,et al. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration , 2000, Nature.